Longitudinal follow-up of SWEDD subjects in the PRECEPT Study - Wikidata - awgldk - TriplyDB

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

http://www.wikidata.org/entity/Q30578973

about

Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease An update on the diagnosis and treatment of Parkinson disease [Molecular imaging in neurological diseases].Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies.Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.Imaging synucleinopathies.Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.Dopamine transporter imaging in essential tremor with and without parkinsonian features.Nonmotor symptoms in subjects without evidence of dopaminergic deficits.Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging.Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.A simple way to distinguish essential tremor from tremulous Parkinson's disease.Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.Genome-wide variant by serum urate interaction in Parkinson's disease.The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.24-Hour Ambulatory Blood Pressure Monitoring in SWEDDs Patients With Parkinsonism.The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al.Diagnostic challenges of Parkinsonism occurring in multiple sclerosis.Parkinson disease: Can dopamine transporter imaging define early PD?Combining clinical and biofluid markers for early Parkinson's disease detection.Screening for dopa-responsive dystonia in patients with Scans Without Evidence of Dopaminergic Deficiency (SWEDD).Classification of Scans Without Evidence of Dopamine Deficit (SWEDD) According to the Olfactory Function.Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit.Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm.Localizing parkinsonism based on focal brain lesions Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?

P2860

Q28601965-32471834-D02D-4483-ADFC-FAC7011AD16D Q30243899-1D1FD534-2229-49D8-907D-FF911C22A6C8 Q31108303-25906CD6-8CD7-4253-B91B-CCF244E2DADE Q34553777-8C89014E-0D2F-4368-AE5E-5144F8FCF7D0 Q36834554-AE209107-618A-4D99-8C96-7D6137AB63CD Q36972794-BAFD05D4-0D21-4E53-80B2-4F91757C2DC9 Q38385278-18466AB1-0590-4AC6-9BCC-C469876F02D0 Q38492560-9676A6E5-7818-42B6-9B1A-E9765463D750 Q38657775-75DEE2CC-13AF-414D-95B1-7B0C5821D9DC Q38734660-741AB704-6323-4726-97AA-5540871994FB Q40041644-E513599D-37A9-4ACB-B201-C9BA41769E28 Q40777631-FC4D25D7-A62D-4E94-9E30-FC4A2DEB04A6 Q41219724-5362DF4A-24BE-4B35-8058-B444982BC064 Q42094454-9A2F5830-13EB-4C77-96F5-027FDA6783C2 Q47888933-1B768EFB-2201-4F6B-BABE-1C215F09A3C5 Q47949427-F9E9BD74-8F4C-432B-B682-46773E74A997 Q47952640-FE349EFE-E596-4CC1-ADB9-26918CD5DEDB Q48075588-E8EF0206-E419-409B-AF51-88DC13687EF1 Q48103234-1B98D33E-7555-43F6-82E9-7FE18D0ABD9E Q48245264-3DC802D0-AFC9-4391-B8A0-FFA205CBB636 Q48338757-BFA8E462-9A47-470F-90D5-8B8B90DBD64E Q48488287-6741DA0C-0811-44F6-8ACA-59ECAE88C009 Q48671361-EB8B4E12-EC74-4556-A6F8-3BBA06652259 Q49202410-719EFCAD-AC76-4898-A052-17B990B78EC1 Q50246838-D57B1694-3148-423C-81C8-84A67C413429 Q52966937-131CB089-BCA6-403A-B008-05D2B883F719 Q55010173-2F2D7D6A-17CD-4E00-B79B-4F1865A704C6 Q55339954-9864681F-84F4-433A-9FC0-E740F43EC634 Q56967259-6E643778-2EE7-4D0D-A44B-D0D74E0BD490 Q58576293-6C6FD2B0-6E5D-4BAD-BA36-A01696C04F37

P2860

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

http://www.wikidata.org/entity/Q30578973

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@ast

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@en

type

label

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@ast

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@en

prefLabel

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@ast

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@en

P1433

Q30578973-34061D85-55AF-4222-8519-6EAF35C69930

P1476

Q30578973-E107FC15-6A36-45B1-911E-599F0BAD65E7

P2093

Q30578973-4134CE5C-5980-4A60-A91D-0579CDC1BAC5

Q30578973-55F84A85-E549-44E1-891B-8DA7596514BD

Q30578973-5EAB916C-2C8C-4DFA-B0B5-C4C28540DDB1

Q30578973-6C1FE4F2-81EE-46BA-BB3B-1AE0CD024A4A

Q30578973-91951150-96D9-4E48-88D5-824F7BC5B068

Q30578973-A909A944-189E-43B6-99B9-3E36843C4F08

Q30578973-EA6A53A8-56FF-4226-A7D2-D83754145FD5

Q30578973-EDBFA2CB-ED2A-42B5-987D-F6B1345D05C2

P2860

Q30578973-1CE00ED6-895D-4FD3-85E7-A910CAF91CD9

Q30578973-269A926F-FF05-4EA4-9B0C-703E1BA251E8

Q30578973-26F1AAF2-1824-463F-8C51-117A0FDA3936

Q30578973-28E10769-EAFB-4C61-B97C-AF7EA230216F

Q30578973-3B669C61-84BA-4DDC-9FD9-B8AF7E34D7CD

Q30578973-48129A0B-D418-4CD5-9431-DB2917B1ACE2

Q30578973-8E333E09-AD46-4DB0-B8E1-FFE8EEABC45A

Q30578973-9700E89F-F1E1-4B49-A9B3-7A95E00FDA0F

Q30578973-98781D43-7303-4AB9-B9A4-A8D4D2EBF1F8

Q30578973-9E6E3622-BA71-4D97-854C-0FE4919B93B8

P304

Q30578973-E5644FEC-5500-4C9A-A779-1B8C1F457407

P31

Q30578973-1B7D7D06-8602-42A3-97C4-9FA7C0C51022

P356

Q30578973-5AC4E636-0681-458D-8196-AA72A45D3BC0

P407

Q30578973-472138FA-880A-4477-90C8-80B410C68711

P433

Q30578973-F4ECA48D-2DDA-44B8-9FD8-967085BC3CC2

P478

Q30578973-CB691F68-39F2-4392-8B13-9CA7AC6671DD

P50

Q30578973-2915FB22-68F6-4E29-AB17-389ED98315B6

P577

Q30578973-545EA970-B3F8-4DB6-889D-F89435749F92

P698

Q30578973-AA79A18B-07C7-4B9A-9D18-B39314083150

P932

Q30578973-9DF8F41B-B38F-460A-9DC6-9B0DD8A7D3B1

P356

WNL.0000000000000424

P1433

P1476

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

@en

P2093

Chris Hyson

http://www.w3.org/2001/XMLSchema#string

Danna Jennings

http://www.w3.org/2001/XMLSchema#string

David Oakes

http://www.w3.org/2001/XMLSchema#string

Ira Shoulson

http://www.w3.org/2001/XMLSchema#string

John Seibyl

http://www.w3.org/2001/XMLSchema#string

Kenneth Marek

http://www.w3.org/2001/XMLSchema#string

Parkinson Study Group PRECEPT Investigators

http://www.w3.org/2001/XMLSchema#string

Shirley Eberly

http://www.w3.org/2001/XMLSchema#string

P2860

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Levodopa and the progression of Parkinson's disease.

Role of dopamine transporter imaging in routine clinical practice.

Role of DAT-SPECT in the diagnostic work up of parkinsonism.

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.

Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries.

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

P304

1791-1797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000000424

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24759846

http://www.w3.org/2001/XMLSchema#string

P932

4035714

http://www.w3.org/2001/XMLSchema#string